Search results for "Fluorobenzene"
showing 10 items of 73 documents
CCDC 953881: Experimental Crystal Structure Determination
2013
Related Article: Huayan Yang, Yu Wang, Huaqi Huang, Lars Gell, Lauri Lehtovaara, Sami Malola, Hannu Hakkinen, Nanfeng Zheng|2013|Nat.Commun.|4|2422|doi:10.1038/ncomms3422
CCDC 1407136: Experimental Crystal Structure Determination
2015
Related Article: Pia Bonakdarzadeh, Fangfang Pan, Elina Kalenius, Ondřej Jurček, Kari Rissanen|2015|Angew.Chem.,Int.Ed.|54|14890|doi:10.1002/anie.201507295
CCDC 1407137: Experimental Crystal Structure Determination
2015
Related Article: Pia Bonakdarzadeh, Fangfang Pan, Elina Kalenius, Ondřej Jurček, Kari Rissanen|2015|Angew.Chem.,Int.Ed.|54|14890|doi:10.1002/anie.201507295
Lipid-Altering Efficacy of Ezetimibe/Simvastatin 10/20 mg Compared to Rosuvastatin 10 mg in High-Risk Patients with and without Type 2 Diabetes Melli…
2010
AIMS: This post hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg (EZE/SIMVA) or rosuvastatin 10 mg (ROSUVA) in uncontrolled high-risk hypercholesterolemic patients with/without type 2 diabetes mellitus (T2DM) despite statin monotherapy. METHODS: Patients (n = 618) at high risk for coronary vascular disease with elevated LDL-C ≥100 and ≤190 mg/dL despite use of statins were randomized 1:1 to double-blind EZE/SIMVA 10/20 mg or ROSUVA 10 mg for 6 weeks. Patients were classified as having T2DM based on ≥1 of the following: diagnosis of T2DM, antidiabetic medication, or FPG ≥126 mg/dL. This analysis evaluated percent changes from baseline in lipids among patients …
Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients.
2007
Increasing evidence suggests that the quality-rather than just the quantity-of low-density lipoproteins (LDLs) exerts a great influence on cardiovascular risk. LDLs comprise multiple subclasses with discrete size and density, and different physicochemical composition, metabolic behaviors, and atherogenicity. Individuals generally cluster into 2 broad subgroups. Most have a predominance of large LDLs, and some have a higher proportion of small particles. Small, dense LDLs are good predictors of cardiovascular events and progression of coronary artery disease. Their predominance has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Tre…
ortho-Metalation of aromatic ethers by yttrium alkyl complexes that contain a linked amido-cyclopentadienyl ligand
2003
Abstract The reaction of the half-sandwich alkyl complex [Y(η5:η1-C5Me4CH2SiMe2NtBu)(CH2SiMe3)(THF)] (1) with anisole smoothly gives the ortho-metalation product [Y(η5:η1-C5Me4CH2SiMe2NtBu)(2-C6H4OMe)(THF)] (2). 3- and 4-Methylanisole as well as phenetole analogously undergo ortho-metalation, whereas thioanisole, N,N′-dimethylaniline, fluorobenzene, and trifluorobenzene do not react with yttrium complex 1. 2-Methylanisole reacts with 1 under activation of the ring methyl group to give the 2-methoxybenzyl complex [Y(η5:η1-C5Me4CH2SiMe2NtBu)(CH2C6H4OMe-2)(THF)] (6). A single-crystal X-ray structure analysis of the 2-anisyl complex 2 revealed a four-legged piano-stool configuration with the me…
CCDC 1530606: Experimental Crystal Structure Determination
2017
Related Article: Huayan Yang, Juanzhu Yan, Yu Wang, Haifeng Su, Lars Gell, Xiaojing Zhao, Chaofa Xu, Boon K. Teo, Hannu Häkkinen , and Nanfeng Zheng|2017|J.Am.Chem.Soc.|139|31|doi:10.1021/jacs.6b10053
Is diabetes the cost to pay for a greater cardiovascular prevention?
2010
The recent JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) trial is another study providing evidence about the effectiveness of statin therapy in reducing cardiovascular risk. Yet, in this study significantly higher glycated hemoglobin levels and incidence rates of diabetes were observed in persons treated with rosuvastatin than the placebo group. It should be noted that adverse effects on glucose metabolism have already been reported, albeit rarely, in previous trials with statins. Although the exact mechanisms involved are unknown, it seems that statins may deteriorate glycemic control by decreasing different metabolites,…
Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: what is the clinical significance ?
2009
Summary Background: Statins have emerged as the global leader in pharmacologic therapy for dyslipidaemia, and rosuvastatin has demonstrated clinical efficacy as well as safety in several clinical trials and postmarketing analyses. Aim: The present article reviewed the effects of rosuvastatin on the quantity and the quality of low-density lipoproteins (LDL). Methods: We searched for and reviewed all the available evidence in a systematic way. A literature search (by Medline and Scopus) was performed using the following headings: ‘LDL-cholesterol’, ‘LDL size’, ‘LDL subclasses’, ‘small dense LDL’, ‘apolipoprotein B, apo B’ and ‘rosuvastatin’ up to 11 November 2008. The authors also manually…
Combined sub-optimal doses of Rosuvastatin and Bexarotene impairs angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox…
2015
Aim: Mononuclear cell (MC) infiltration into the arterial subendothelium is a key event in atherogenesis. Rosuvastatin (Rosu) and bexarotene (Bex) exert anti-inflammatory activity, but serious dose-related adverse effects have emerged. The need for safer and effective strategies to prevent and treat atherosclerosis led us to test the effect of combined use of both drugs on angiotensin II (Ang-II)-induced arterial MC recruitment. Results: Vehicle, Rosu (10–30 nM), Bex (0.3–1 μM), or a combination of both were administered to human umbilical arterial endothelial cells (HUAECs) 20 h before stimulation with 1 μM Ang-II (4 h). Surprisingly, a combination of Rosu (10 nM)+Bex (0.3 μM), which did n…